SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Ji Young Yun, Jae Woo Kim, Hee-Tae Kim, Sun Ju Chung, Jong-Min Kim, Jin Whan Cho, Jee-Young Lee, Ha Neul Lee, Sooyeoun You, Eungseok Oh, Heejeong Jeong, Young Eun Kim, Han-Joon Kim, Won Yong Lee, Beom S. Jeon, Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: A double-blind, randomized study, Movement Disorders, 2015, 30, 2
  2. 2
    Doris Hexsel, Mariana Soirefmann, Manoela D. Porto, Carolina Siega, Juliana Schilling-Souza, Ticiana C. Rodrigues, Fields of Muscular and Anhidrotic Effects of 2 Botulinum Toxin-A Commercial Preparations, Dermatologic Surgery, 2015, 41, S110

    CrossRef

  3. 3
    Benoit Peyronnet, Mathieu Roumiguié, Evelyne Castel-Lacanal, Julien Guillotreau, Bernard Malavaud, Philippe Marque, Pascal Rischmann, Xavier Gamé, Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity, Neurourology and Urodynamics, 2015, 34, 7
  4. 4
    Zeynep D. Akdeniz, Mehmet Bayramiçli, Filiz Ateş, Naziye Özkan, Can A. Yucesoy, Feriha Ercan, The role of botulinum toxin type a-induced motor endplates after peripheral nerve repair, Muscle & Nerve, 2015, 52, 3
  5. 5
    Paul G. Mathew, A Critical Evaluation of Migraine Trigger Site Deactivation Surgery, Headache: The Journal of Head and Face Pain, 2014, 54, 1
  6. 6
    Yohei Mukai, Yoshimitsu Shimatani, Wataru Sako, Kotaro Asanuma, Hiroyuki Nodera, Takashi Sakamoto, Yuishin Izumi, Tomoko Kohda, Shunji Kozaki, Ryuji Kaji, Comparison between botulinum neurotoxin type A2 and type A1 by electrophysiological study in healthy individuals, Toxicon, 2014, 81, 32

    CrossRef

  7. 7
    Sung-Beom Kim, Bhupal Ban, Keun-Suk Jung, Gi-Hyeok Yang, A Pharmacodynamic Comparison Study of Different Botulinum Toxin Type A Preparations, Dermatologic Surgery, 2013, 39, 1pt2
  8. 8
    Robert A. Hauser, Daniel Truong, Jean Hubble, Chandra Coleman, Jean-Luc Beffy, Stephen Chang, Philippe Picaut, AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies, Journal of Neural Transmission, 2013, 120, 2, 299

    CrossRef

  9. 9
    Roberto Eleopra, Cesare Montecucco, Grazia Devigili, Christian Lettieri, Sara Rinaldo, Lorenzo Verriello, Marco Pirazzini, Paola Caccin, Ornella Rossetto, Botulinum neurotoxin serotype D is poorly effective in humans: An in vivo electrophysiological study, Clinical Neurophysiology, 2013, 124, 5, 999

    CrossRef

  10. 10
    Myung Eun Chung, Dae Heon Song, Joo Hyun Park, Comparative Study of Biological Activity of Four Botulinum Toxin Type A Preparations in Mice, Dermatologic Surgery, 2013, 39, 1pt2
  11. 11
    Hanan Mohamed El Kahky, Heba Mahmoud Diab, Dalia Gamal Aly, Nehal Magdi Farag, Efficacy of Onabotulinum Toxin A (Botox) versus Abobotulinum Toxin A (Dysport) Using a Conversion Factor (1 : 2.5) in Treatment of Primary Palmar Hyperhidrosis, Dermatology Research and Practice, 2013, 2013, 1

    CrossRef

  12. 12
    Ching-Hsin Chang, Yu-Hua Fan, Alex T.L. Lin, Kuang-Kuo Chen, Long-term clinical value of urethral sphincter injection of onabotulinumtoxinA for patients with acontractile bladder, Urological Science, 2013, 24, 1, 14

    CrossRef

  13. 13
    Esther V. Hobson, Alexander McGeachan, Ammar Al-Chalabi, Siddharthan Chandran, Francesca Crawley, David Dick, Colette Donaghy, John Ealing, Cathy M. Ellis, George Gorrie, C. Oliver Hanemann, Timothy Harrower, Agam Jung, Tahir Majeed, Andrea Malaspina, Karen Morrison, Richard W. Orrell, Hardev Pall, Ashwin Pinto, Kevin Talbot, Martin R. Turner, Timothy L. Williams, Carolyn A. Young, Pamela J. Shaw, Christopher J. McDermott, Management of sialorrhoea in motor neuron disease: A survey of current UK practice, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 7-8, 521

    CrossRef

  14. 14
    Marco Pirazzini, Tina Henke, Ornella Rossetto, Stefan Mahrhold, Nadja Krez, Andreas Rummel, Cesare Montecucco, Thomas Binz, Neutralisation of specific surface carboxylates speeds up translocation of botulinum neurotoxin type B enzymatic domain, FEBS Letters, 2013, 587, 23, 3831

    CrossRef

  15. 15
    Saedeh Dadgar, Zack Ramjan, Wely B. Floriano, Paclitaxel Is an Inhibitor and Its Boron Dipyrromethene Derivative Is a Fluorescent Recognition Agent for Botulinum Neurotoxin Subtype A, Journal of Medicinal Chemistry, 2013, 56, 7, 2791

    CrossRef

  16. 16
    Ron S. Broide, John Rubino, Gregory S. Nicholson, Maria C. Ardila, Meenakshi S. Brown, K. Roger Aoki, Joseph Francis, The rat Digit Abduction Score (DAS) assay: A physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis, Toxicon, 2013, 71, 18

    CrossRef

  17. 17
    Edward A. Bittner, J.A. Jeevendra Martyn, Pharmacology and Physiology for Anesthesia, 2013,

    CrossRef

  18. 18
    Andy Pickett, Animal Studies with Botulinum Toxins May Produce Misleading Results, Anesthesia & Analgesia, 2012, 115, 3, 736

    CrossRef

  19. 19
    Giuliano Queiroz Mostachio, Maricy Apparício, Tathiana Ferguson Motheo, Aracélle Elisane Alves, Wilter Ricardo Russiano Vicente, Intra-prostatic injection of botulinum toxin type A in treatment of dogs with spontaneous benign prostatic hyperplasia, Animal Reproduction Science, 2012, 133, 3-4, 224

    CrossRef

  20. 20
    Nicole Calakos, Handbook of Dystonia, 2012,

    CrossRef

  21. 21
    Carl H. Manstein, Omar E. Beidas, Comparing Clinical Efficacy of Botox and Dysport in a Small Group of Patients, Plastic and Reconstructive Surgery, 2011, 128, 1, 26e

    CrossRef

  22. 22
    Erez Bakshi, Morris E. Hartstein, Compositional differences among commercially available botulinum toxin type A, Current Opinion in Ophthalmology, 2011, 22, 5, 407

    CrossRef

  23. 23
    Gerhard H.H. Müller-Schwefe, Michael A. Überall, Dysport® for the treatment of myofascial back pain: Results from an open-label, Phase II, randomized, multicenter, dose-ranging study, Scandinavian Journal of Pain, 2011, 2, 1, 25

    CrossRef

  24. 24
    KEEWON KIM, HYUNG-IK SHIN, BUM SUN KWON, SANG JUN KIM, IL-YOUNG JUNG, MOON SUK BANG, Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy: a randomized, double-blinded, controlled multicentre clinical trial, Developmental Medicine & Child Neurology, 2011, 53, 3
  25. 25
    Andy Pickett, Raymond L. Rosales, New Trends in the Science of Botulinum Toxin-A as Applied in Dystonia, International Journal of Neuroscience, 2011, 121, S1, 22

    CrossRef

  26. 26
    Raymond L. Rosales, Mary Mildred Delgado-Delos Santos, Arlene R. Ng, Rosalia Teleg, Marita Dantes, Lillian V. Lee, Hubert H. Fernandez, The Broadening Application of Chemodenervation in X-Linked Dystonia-Parkinsonism (Part I): Muscle Afferent Block Versus Botulinum Toxin-A in Cervical and Limb Dystonias, International Journal of Neuroscience, 2011, 121, S1, 35

    CrossRef

  27. 27
    Raymond L. Rosales, Arlene R. Ng, Mary Mildred Delgado-Delos Santos, Hubert H. Fernandez, The Broadening Application of Chemodenervation in X-Linked Dystonia-Parkinsonism (Part II): An Open-Label Experience With Botulinum Toxin-A (Dysport®) Injections for Oromandibular, Lingual, and Truncal-Axial Dystonias, International Journal of Neuroscience, 2011, 121, S1, 44

    CrossRef

  28. 28
    Raymond L. Rosales, Petr Kanovsky, Hubert H. Fernandez, What’s the “catch” in upper-limb post-stroke spasticity: Expanding the role of botulinum toxin applications, Parkinsonism & Related Disorders, 2011, 17, S3

    CrossRef

  29. 29
    Behrad Elmiyeh, Vyas M. N. Prasad, Tahwinder Upile, Nick Saunders, Bryan D. Youl, Ruth Epstein, John S. Rubin, A single-centre retrospective review of unilateral and bilateral Dysport®injections in adductor spasmodic dysphonia, Logopedics Phoniatrics Vocology, 2010, 35, 1, 39

    CrossRef

  30. 30
    Timothy Corcoran Flynn, Botulinum Toxin, American Journal of Clinical Dermatology, 2010, 11, 3, 183

    CrossRef

  31. 31
    Arzu Coban, Zeliha Matur, Hasmet A. Hanagasi, Yesim Parman, Iatrogenic Botulism After Botulinum Toxin Type A Injections, Clinical Neuropharmacology, 2010, 33, 3, 158

    CrossRef

  32. 32
    B. Poulain, La neurotoxine botulinique, Revue Neurologique, 2010, 166, 1, 7

    CrossRef

  33. 33
    R. L. Rosales, D. Dressler, On muscle spindles, dystonia and botulinum toxin, European Journal of Neurology, 2010, 17,
  34. 34
    Erisela Qerama, Anders Fuglsang-Frederiksen, Troels S Jensen, The role of botulinum toxin in management of pain: an evidence-based review, Current Opinion in Anaesthesiology, 2010, 23, 5, 602

    CrossRef

  35. 35
    Hossein Salour, Babak Bagheri, Maryam Aletaha, Babak Babsharif, Mandana Kleshadi, Mohammad Abrishami, Abbas Bagheri, Transcutaneous Dysport Injection for Treatment of Upper Eyelid Retraction Associated with Thyroid Eye Disease, Orbit, 2010, 29, 2, 114

    CrossRef

  36. 36
    Erle C. H. Lim, Raymond C. S. Seet, Use of botulinum toxin in the neurology clinic, Nature Reviews Neurology, 2010, 6, 11, 624

    CrossRef

  37. 37
    Raymond L. Rosales, X-Linked Dystonia Parkinsonism: Clinical Phenotype, Genetics and Therapeutics, Journal of Movement Disorders, 2010, 3, 2, 32

    CrossRef

  38. 38
    José Francisco, Isabel Pareés Moreno, Toxina Botulínica, 2010,

    CrossRef

  39. 39
    Luca Carli, Cesare Montecucco, Ornella Rossetto, Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg, Muscle & Nerve, 2009, 40, 3
  40. 40
    Lisa Shaw, Helen Rodgers, Botulinum toxin type A for upper limb spasticity after stroke, Expert Review of Neurotherapeutics, 2009, 9, 12, 1713

    CrossRef

  41. 41
    Jae Ho Shin, Chan Jeon, Kyung In Woo, Yoon Duck Kim, Clinical Comparability of Dysport and Botox in Essential Blepharospasm, Journal of the Korean Ophthalmological Society, 2009, 50, 3, 331

    CrossRef

  42. 42
    SYRUS KARSAI, CHRISTIAN RAULIN, Current Evidence on the Unit Equivalence of Different Botulinum Neurotoxin A Formulations and Recommendations for Clinical Practice in Dermatology, Dermatologic Surgery, 2009, 35, 1, 1

    CrossRef

  43. 43
    Kai Wohlfarth, Thomas Sycha, Danièle Ranoux, Hans Naver, David Caird, Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment?, Current Medical Research and Opinion, 2009, 25, 7, 1573

    CrossRef

  44. 44
    Andy Pickett, Dysport®: Pharmacological properties and factors that influence toxin action, Toxicon, 2009, 54, 5, 683

    CrossRef

  45. 45
    Marissa Barlaan Lukban, Raymond L. Rosales, Dirk Dressler, Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence, Journal of Neural Transmission, 2009, 116, 3, 319

    CrossRef

  46. 46
    Federico Fogolari, Silvio C.E. Tosatto, Lucia Muraro, Cesare Montecucco, Electric dipole reorientation in the interaction of botulinum neurotoxins with neuronal membranes, FEBS Letters, 2009, 583, 14, 2321

    CrossRef

  47. 47
    C. Beylot, Les différentes toxines botuliques et leurs spécificités, Annales de Dermatologie et de Vénéréologie, 2009, 136, S77

    CrossRef

  48. 48
    Kerstin Müller, Eilhard Mix, Fereshte Adib Saberi, Dirk Dressler, Reiner Benecke, Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity, Journal of Neural Transmission, 2009, 116, 5, 579

    CrossRef

  49. 49
    Takashi Sakamoto, Yasushi Torii, Motohide Takahashi, Setsuji Ishida, Yoshitaka Goto, Hirotoshi Nakano, Tetsuhiro Harakawa, Akihiro Ginnaga, Shunji Kozaki, Ryuji Kaji, Quantitative determination of the biological activity of botulinum toxin type A by measuring the compound muscle action potential (CMAP) in rats, Toxicon, 2009, 54, 6, 857

    CrossRef

  50. 50
    Gottfried Kranz, Dietrich Haubenberger, Bernhard Voller, Martin Posch, Peter Schnider, Eduard Auff, Thomas Sycha, Respective potencies of Botox® and Dysport® in a human skin model: A randomized, double-blind study, Movement Disorders, 2009, 24, 2
  51. 51
    Samuel Ignacio Pascual-Pascual, Ignacio Pascual-Castroviejo, Safety of botulinum toxin type A in children younger than 2 years, European Journal of Paediatric Neurology, 2009, 13, 6, 511

    CrossRef

  52. 52
    K. Wohlfarth, I. Schwandt, F. Wegner, T. Jürgens, G. Gelbrich, A. Wagner, U. Bogdahn, W. Schulte-Mattler, Biological activity of two botulinum toxin type A complexes (Dysport® and Botox®) in volunteers, Journal of Neurology, 2008, 255, 12, 1932

    CrossRef

  53. 53
    E. C.-H. Lim, R. C. S. Seet, Botulinum toxin: description of injection techniques and examination of controversies surrounding toxin diffusion, Acta Neurologica Scandinavica, 2008, 117, 2
  54. 54
    A. Pickett, D. Caird, Comparison of type a botulinum toxin products in clinical use, Journal of Clinical Pharmacy and Therapeutics, 2008, 33, 3
  55. 55
    Andy Pickett, Stephen Dodd, Berthold Rzany, Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications, Journal of Cosmetic and Laser Therapy, 2008, 10, 3, 181

    CrossRef

  56. 56
    W. J. Schulte-Mattler, E. Leinisch, Evidence based medicine on the use of botulinum toxin for headache disorders, Journal of Neural Transmission, 2008, 115, 4, 647

    CrossRef

  57. 57
    R. L. Rosales, A. S. Chua-Yap, Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity, Journal of Neural Transmission, 2008, 115, 4, 617

    CrossRef

  58. 58
    Johannes M.H. Hennings, Eike Krause, Kai Bötzel, Thomas C. Wetter, Successful treatment of tardive lingual dystonia with botulinum toxin: Case report and review of the literature, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 5, 1167

    CrossRef

  59. 59
    Eric A. Johnson, Cesare Montecucco, Neuromuscular Junction Disorders, 2008,

    CrossRef

  60. 60
    Rita Meyer, xPharm: The Comprehensive Pharmacology Reference, 2008,

    CrossRef

  61. 61
    Kok-Yuen Ho, Kian-Hian Tan, Botulinum toxin A for myofascial trigger point injection: A qualitative systematic review, European Journal of Pain, 2007, 11, 5
  62. 62
    Laura Bonanni, Astrid Thomas, Sara Varanese, Vincenzo Scorrano, Marco Onofrj, Botulinum toxin treatment of lateral axial dystonia in parkinsonism, Movement Disorders, 2007, 22, 14
  63. 63
    Frederick G Freitag, Botulinum toxin type A in chronic migraine, Expert Review of Neurotherapeutics, 2007, 7, 5, 463

    CrossRef

  64. 64
    Ada Trindade de Almeida, Koenraad De Boulle, Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications, Journal of Cosmetic and Laser Therapy, 2007, 9, s1, 17

    CrossRef

  65. 65
    Wolfgang H Jost, Efficacy and safety of botulinum neurotoxin type A free of complexing proteins (NT 201) in cervical dystonia and blepharospasm, Future Neurology, 2007, 2, 5, 485

    CrossRef

  66. 66
    Michael Akbar, Rainer Abel, Thorsten M. Seyler, Hans J. Gerner, Klaus Möhring, Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction, BJU International, 2007, 100, 3
  67. 67
    Wilhelm J. Schulte-Mattler, Elke Leinisch, Role of botulinum toxin in migraine therapy, Drug Development Research, 2007, 68, 7
  68. 68
    Woo H. Choi, Chang W. Song, Yong B. Kim, Chang S. Ha, Gi-H. Yang, Hee-D. Woo, Hyun H. Jung, Woo S. Koh, Skeletal Muscle Atrophy Induced by Intramuscular Repeated Dose of Botulinum Toxin Type A in Rats, Drug and Chemical Toxicology, 2007, 30, 3, 217

    CrossRef

  69. 69
    Daniel D. Truong, Wolfgang H. Jost, Botulinum toxin: Clinical use, Parkinsonism & Related Disorders, 2006, 12, 6, 331

    CrossRef

  70. 70
    Florian Heinen, Guy Molenaers, Charlie Fairhurst, Lucinda J. Carr, Kaat Desloovere, Emmanuelle Chaleat Valayer, Edith Morel, Antigone S. Papavassiliou, Kristina Tedroff, S. Ignacio Pascual-Pascual, Günther Bernert, Steffen Berweck, Guiseppe Di Rosa, Elisabeth Kolanowski, Ingeborg Krägeloh-Mann, European consensus table 2006 on botulinum toxin for children with cerebral palsy, European Journal of Paediatric Neurology, 2006, 10, 5-6, 215

    CrossRef

  71. 71
    Nicole Calakos, Handbook of Dystonia, 2006,

    CrossRef

  72. 72
    Mehrdad Alemozaffar, Anurag K. Das, Bladder Injections for Refractory Overactive Bladder,